EP3072528A1 — Composition comprising vemurafenib and cationic copolymer based on methacrylates
Assigned to Ratiopharm GmbH · Expires 2016-09-28 · 10y expired
What this patent protects
The present invention relates to a premix comprising vemurafenib choline or vemurafenib as free form and cationic copolymer based on methacrylates and to oral dosage forms comprising said premix. Further, the invention relates to a process for producing said premix comprising vem…
USPTO Abstract
The present invention relates to a premix comprising vemurafenib choline or vemurafenib as free form and cationic copolymer based on methacrylates and to oral dosage forms comprising said premix. Further, the invention relates to a process for producing said premix comprising vemurafenib choline or vemurafenib as free form and cationic copolymer based on methacrylates and to the corresponding process of producing an oral dosage form containing the premix of the invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.